J 2019

Simplified novel prognostic score for real-life older adults with multiple myelomaregistry-based analysis

RADOCHA, J., Roman HÁJEK, Lucie BROŽOVÁ, Luděk POUR, I. ŠPIČKA et. al.

Basic information

Original name

Simplified novel prognostic score for real-life older adults with multiple myelomaregistry-based analysis

Authors

RADOCHA, J. (203 Czech Republic, guarantor), Roman HÁJEK (203 Czech Republic), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution), Luděk POUR (203 Czech Republic, belonging to the institution), I. ŠPIČKA (203 Czech Republic), J. MINAŘÍK (203 Czech Republic), E. GREGORA (203 Czech Republic), A. JUNGOVÁ (203 Czech Republic), T. JELÍNEK (203 Czech Republic), A. HEINDORFER (203 Czech Republic), M. SÝKORA (203 Czech Republic) and V. MAISNAR (203 Czech Republic)

Edition

Annals of hematology, New York, Springer Verlag, 2019, 0939-5555

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.904

RIV identification code

RIV/00216224:14110/19:00109477

Organization unit

Faculty of Medicine

UT WoS

000461545800016

Keywords in English

Multiple myeloma; Older adults; Prognostic factors

Tags

International impact, Reviewed
Změněno: 17/4/2019 13:00, Soňa Böhmová

Abstract

V originále

The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over 65years with symptomatic myeloma were included. The four major parameters with impact on survival were identified: male gender, age>75, creatinine >152mol/L, and ECOG performance status 2-4. The patients were scored as good (0 points), intermediate good (1 point), intermediate poor (2 points), poor (3-4 points). Patients (1410 MM) were included. Median OS (months) was 65.7 (95% CI 49.8-81.7) for good, 51.0 (44.1-57.8) for intermediate good, 32.2 (26.2-38.2) for intermediate poor, and 18.9 (15.1-22.7) for poor. The differences in OS were statistically significant (p<0.0001). Good score was used as reference for hazard ratios, which for each other score were 1.43 (1.09-1.84) for intermediate good, 2.58 (2.00-3.33) for intermediate poor, and 3.88 (2.94-5.10) for poor. Time to progression showed medians (months) 20.5 (17.4-62.4) for good, 19.3 (17.0-21.7) for intermediate good, 19.6 (16.2-23.0) for intermediate poor, and 13.0 (10.8-15.2) for poor. The suggested scoring system provides readily available information about the prognosis of MM patients above 65years.